Table 1 Subject characteristics
From: Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
Subjects | Control group (n = 35) | Placebo group (n = 30) | YXQN group (n = 31) | P value |
|---|---|---|---|---|
Age (yr) | 66.8 ± 7.7 | 67.1 ± 10.2 | 68.6 ± 9.2 | 0.89 |
Men/Women | 21/14 | 19/11 | 18/13 | - |
Disease duration | - | 6.1 ± 4.9 | 5.9 ± 4.7 | 0.17 |
UPDRS score | - | 37.59 ± 10.51 | 38.35 ± 6.78 | 0.23 |
Levodopa/DCI (mg/day) | - | 412.5 ± 162.8 | 421.3 ± 142.9 | 0.65 |
Pramipexole(mg/day) | - | 1.11 ± 0.39 | 1.03 ± 0.78 | 0.08 |
Entacapone (mg/day) | - | 198.28 ± 88.47 | 203.67 ± 78.38 | 0.12 |
Selegiline hydrochloride (mg/day) | - | 8.33 ± 6.94 | 8.21 ± 3.76 | 0.26 |
Adamantatamine (mg/day) | - | 118.73 ± 96.59 | 116.31 ± 89.6 | 0.19 |
Artane hydrochloride (mg/day) | - | 4.82 ± 2.91 | 4.65 ± 2.36 | 0.08 |